Clinical trials: HYPERGLYCEMIA
Diabetes Mellitus, Type 2, Pre-diabetes
Dietary Intervention in Type-2 Diabetes and Pre-Diabetes
The primary purpose of this research is to demonstrate the therapeutic effects of implementing a well-formulated low carbohydrate lifestyle program over 2 years in patients with type 2 diabetes, pre-diabetes, and metabolic…
- Conditions
- Diabetes Mellitus, Type 2, Pre-diabetes, Metabolic Syndrome
- Trial name
- NCT02519309
- Testing
- Virta Program
- Where
- United States
- Volunteers
- 465 people
- Sponsor
- Virta Health
Type 2 Diabetes Mellitus
A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DM
Type 2 diabetes mellitus is a complex, chronic disease that requires a comprehensive treatment plan aimed at meeting multitude therapeutic targets associated with micro- and macro-vascular risk reduction.
- Trial name
- NCT03090464
- Testing
- Use of digital disease management tool
- Where
- 46 sites in United States
- Volunteers
- 328 people
- Sponsor
- AstraZeneca
Blood Sugar; High, Overweight and Obesity
Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.
- Conditions
- Blood Sugar; High, Overweight and Obesity, Fat Loss, GLP-1
- Trial name
- RCT (NCT07141472)
- Testing
- GB
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Lawry Han
Diabetes Mellitus, Type 2, Atherosclerosis
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
This study will evaluate the effect of ACZ885 on vascular function in patients with documented atherosclerotic disease and T2DM or IGT.
- Conditions
- Diabetes Mellitus, Type 2, Atherosclerosis, Prediabetic State
- Trial name
- NCT00995930
- Testing
- ACZ885
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 189 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus
A Two Part Study of Peroral Insulin in Type 2 Diabetes
Insulin is normally not bioavailable when taken through the oral route, as degradation of the molecule may occur both in the ventricle and in the intestine.
- Trial name
- ORA2 (NCT00990444)
- Testing
- Insulin in Dextran Matrix
- Where
- Sweden
- Volunteers
- 32 people
- Sponsor
- Bows Pharmaceuticals AG
Metabolic Syndrome, Impaired Glucose Tolerance
Evaluation of Low Source of Signal in SCOUT DS
The overall objective of this study is to increase the number of dark skin tone individuals in the data set and evaluate if this increase in dark skin tone data has an impact on the accuracy of the SCOUT DS Diabetes Risk Score…
- Conditions
- Metabolic Syndrome, Impaired Glucose Tolerance, Gestational Diabetes
- Trial name
- LSS (NCT01339637)
- Where
- 5 sites in United States
- Volunteers
- 196 people
- Sponsor
- VeraLight, Inc.
Diabetes Mellitus, Type 2
Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients
This was a four month dose ranging study followed by a 24 to 48 month extension at the selected dose to characterize the safety and efficacy of the injectable IL-1B (interleukin 1, beta) antagonist canakinumab in the treatment of…
- Trial name
- NCT00900146
- Testing
- Canakinumab, Metformin
- Where
- 106 sites in United States, Argentina and 12 more
- Volunteers
- 556 people
- Sponsor
- Novartis
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
This was a 10-week, placebo-controlled, randomized study to investigate the effect of injectable IL-1B antagonist, Canakinumab , in participants with impaired glucose tolerance or Type 2 Diabetes Mellitus (T2DM) already treated…
- Trial name
- NCT01068860
- Testing
- Canakinumab 150 mg
- Where
- 52 sites in United States, Australia and 5 more
- Volunteers
- 246 people
- Sponsor
- Novartis
Postprandial Hyperglycemia
Investigation of Milk Peptides on Postprandial Blood Glucose Profile
Aim of the study is to investigate the effect of two different dosages of milk peptides on postprandial blood glucose profile in prediabetic subjects compared to placebo.
- Trial name
- NCT03932695
- Testing
- Low dose milk peptide, High Dose milk peptide
- Where
- Germany
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Ingredia S.A.
Diabetes Mellitus, Type 2
A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (what the body does to the medication) and pharmacodynamics (what the medication does to the body) of treatment with JNJ-41443532 relative to…
- Trial name
- NCT01230749
- Testing
- JNJ-41443532, Pioglitazone 30 mg
- Volunteers
- 89 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Postprandial Hyperglycemia
Determination of the GI and II Values of Soft Drink and Soft Drink With Sugardown™
This study was a partly controlled laboratory-based study comparing the glycemic and insulinemic indices of 3 test meals containing soft drink alone or with SUGARDOWN™ (Galactomannan) in overweight adults.
- Trial name
- NCT03374501
- Testing
- Sugardown™, Soft drink
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Boston Therapeutics
Acute Heart Failure
Heart & Diabetes - Feasibility Study
The main purpose of this study is to validate an intensive protocol of insulin infusion and subsequent subcutaneous insulin administration with the support of continuous glucose monitoring, in addition to reference finger-stick…
- Trial name
- NCT00922402
- Testing
- Intensive insulin infusion
- Where
- 2 sites in Italy
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Pre Diabetes, Impaired Glucose Tolerance
Effect of F. Prausnitzii on Glycemic Control
The microbiota is associated with a wide spectrum of diseases including diabetes and non-alcoholic fatty liver disease. In this study we will investigate if the bacteria F.
- Conditions
- Pre Diabetes, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT04938843
- Testing
- F. prausnitzii and D. piger
- Where
- Sweden
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- MetaboGen AB
Pre-diabetes, Diabetes Mellitus
Artificial Intelligence to Improve Cardiometabolic Risk Evaluation Using CT Scans
To validate the ability of the FatHealth algorithm to identify individuals with pre-diabetes and with type 2 diabetes mellitus
- Trial name
- ACRE-CT (NCT05058690)
- Testing
- Oral Glucose Tolerance Test
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Caristo Diagnostics Limited
Diabetes Mellitus, Pre-Diabetes
Study to Evaluate Safety and Efficacy of PreCrea® on Subjects With Higher Than Normal Blood Sugar Levels
The purpose of the study is to evaluate the efficacy and safety of PreCrea® on subjects with higher than normal blood sugar levels.
- Conditions
- Diabetes Mellitus, Pre-Diabetes, Hyperglycemia, Metabolic Syndrome
- Trial name
- Precrea (NCT02189005)
- Testing
- Study dietary supplement (PreCrea 600 mg capsules)
- Where
- 6 sites in India
- Volunteers
- 210 people
- Sponsor
- Joe Fenn
Respiratory Disorder, Cardiovascular Diseases
Study of RE.DOCTOR Vitals® Software Accuracy
The purpose of this observational trial is to advance digital health monitoring through the analysis of Photoplethysmography (PPG) waveforms collected via RE.DOCTOR Vitals software.
- Conditions
- Respiratory Disorder, Cardiovascular Diseases, Diabetes, Pre-Diabetes
- Trial name
- RE-VITAL (NCT06237322)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- RE.DOCTOR LLC
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Comparison of Glycemic Control Among Diabetics Using Three Different Pen Needles
Anxiety about needles is a commonly expressed concern by diabetics about beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of currently marketed pen needles may…
- Trial name
- NCT00928057
- Testing
- 4mm x 32G pen needle, 8mm x 31G pen needle, 5mm x 31G pen needle
- Where
- 4 sites in United States
- Volunteers
- 173 people
- Sponsor
- Becton, Dickinson and Company
Diabetes Mellitus
Intraoperative Dexamethasone and Its Effect on Hyperglycemia
To study the effect of intra-operative dexamethasone on the management of post-operative blood sugar in diabetic patients.
- Trial name
- NCT03646916
- Testing
- Dexamethasone, No dexamethasone
- Where
- United States
- Sponsor
- Ascension Health
Blood Sugar; High, Overweight and Obesity
Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.
- Conditions
- Blood Sugar; High, Overweight and Obesity, Fat Burn, Obesity
- Trial name
- NCT06333496
- Testing
- GLP-1 Booster (GB)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Alpine Biotech LLC
Impaired Glucose Tolerance
GLU-xx Formulations in Individuals With Impaired Glucose Tolerance
The purpose of this study is to determine a safe,tolerable and efficacious dose of GLU-xx.
- Trial name
- NCT01468376
- Testing
- GLU-01, GLU-02, GLU-03
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Afexa Life Sciences Inc